A5101896647- Acute Lymphoblastic Leukemia research
- CAR-T cell therapy research
- Retinoids in leukemia and cellular processes
- Lung Cancer Treatments and Mutations
- Immunodeficiency and Autoimmune Disorders
- Radiomics and Machine Learning in Medical Imaging
- Acute Myeloid Leukemia Research
- Lymphoma Diagnosis and Treatment
- Lung Cancer Diagnosis and Treatment
- Hematopoietic Stem Cell Transplantation
- Chronic Lymphocytic Leukemia Research
Institute of Hematology & Blood Diseases Hospital
2023-2025
Chinese Academy of Medical Sciences & Peking Union Medical College
2024-2025
Academy of Medical Sciences
2024
Sun Yat-sen University Cancer Center
2014
Sun Yat-sen University
2014
The use of cytarabine (Ara-C) in treating acute promyelocytic leukemia (APL) is controversial. This study was conducted to demonstrate the effect treatment with or without Ara-C on long-term event-free survival (EFS) overall (OS). All patients received all-trans retinoic acid (ATRA) + arsenic trioxide (ATO) induction therapy, followed by course idarubicin (IDA) and ATO, then were randomly allocated 2 groups for consolidation daunorubicin (DNR) group DNR, DNR (DA) Ara-C. Maintenance therapy...
<title>Abstract</title> The conventional intensity of chemotherapy has reached its limit. Despite the efficacy blinatumomab in B-cell acute lymphoblastic leukemia (B-ALL) adults with measurable residual disease (MRD) been proved, studies children MRD positivity (MRD+) are still lacking. We conducted an exploratory trial 14 days monotherapy combination a B-ALL protocol pediatric patients MRD+ at day 46 and evaluated early safety this approach (Blin-14d-therapy, ChiCTR2100053318, registered on...
Topic: 25. Gene therapy, cellular immunotherapy and vaccination - Clinical Background: Despite the efficacy of blinatunomab (blin) in adults with measurable residual disease (MRD) has been proved [Gökbuget, Blood 2018], studies children primary MRD positivity (MRD+) are still lacking. Furthermore, conventional single course blin takes 4 weeks is associated a high risk ICANS. Aims: Herein, we conducted an exploratory trial 14 days monotherapy (blin-14days-therapy) combination ALL-Chemotherapy...
Topic: 35. Quality of life and palliative care Background: Acute promyelocytic leukemia (APL) is characterized by the formation a PML-RARa fusion gene almost curable disease with use all-trans retinoic acid (ATRA) arsenicals, including arsenic trioxide (ATO) Realgar-Indigo naturalis formula (RIF). Now, purpose patients to pursue better quality life. This cross sectional study determine concentration in tissues whether retention negatively related Aims: To investigate health-related (HRQoL)...